Document is current
Any future updates will be listed below
-
Authors
Kamp, D. https://orcid.org/0009-0006-9118-4731
May, A. M.
van Velzen, M. J. M.
Mook, S.
Freund, J. E.
Mostert, B. https://orcid.org/0000-0001-5193-0820
Verhoeven, R. H. A.
van Laarhoven, H. W. M.
Haj Mohammad, N.
- License Information
-
More Information
Article History
Received: 10 September 2025
Revised: 19 January 2026
Accepted: 19 February 2026
First Online: 26 March 2026
Competing interests
: HWMvL has acted as a consultant or in an advisory role for Auristone, Incyte, Merck, Myeloid, Servier; and has received research funding and/or medication/material supply from Amphera, Anocca, Astellas, AstraZeneca, Beigene, Boehringer, BMS, Daiichy-Sankyo, Dragonfly, MSD, MyeloidTx, ORCA, Servier and speaker roles for Astellas, Beigene, Benecke, BMS, Daiichy-Sankyo, JAAP, Medtalks, Novartis, Springer, Travel Congress Management B.V, and has received travel support from AstraZeneca. NHM has acted as a consultant or in an advisory role for BMS, Astra Zeneca, Servier, MSD, and Eli Lilly; and has received research funding and/or medication/material supply from Servier. RHAV has received research funding from BMS and Amgen and has acted as consultant for Daiichi Sankyo. BM: has received research funding and/or medication supply from BMS and Pfizer; and has acted as a consultant or in an advisory role for Amgen. AMM, MJMvV, SM, JEF and DK declare no conflicts of interest.
: This study did not require approval from an Institutional Review Board in the Netherlands, as determined by the Central Committee on Research Involving Human Subjects. However, it was approved by the Privacy Review Board of the Netherlands Cancer Registry (request number K19.288) and the scientific committee of the Dutch Upper GI Cancer Group. The study was approved in accordance with the Declaration of Helsinki.
